Burning mouth syndrome
Conditions
Interventions
Burning mouth syndrome patient group :None
Healthy control group:None
Sponsors
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for BMS subjects (1) Meet the diagnostic criteria for BMS; (2) Aged >= 18 and = 18 and <= 70 years, regardless of gender; (2) No history of oral pain or burning sensation; (3) No history of systemic diseases or mental disorders.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for BMS subjects (1) Presence of detectable organic lesions in the oral mucosa, teeth, or periodontal tissues accompanied by pain, such as ulcers, deep caries, or periodontitis; (2) History of facial nerve pain, such as trigeminal neuralgia or glossopharyngeal neuralgia; (3) History of head and neck radiotherapy, associated with salivary gland disease or other oral mucosal diseases; (4) Systemic inflammation, autoimmune diseases, or serious diseases of major organs such as the heart, liver, kidney, and blood system; (5) Primary mental illnesses (including severe depression, severe personality disorders) or history of substance abuse (excluding caffeine or nicotine); (6) Use of anesthetics or anti-anxiety/depression medications within the last month; (7) Coexisting other chronic pain-related diseases (such as fibromyalgia, chronic headaches, postherpetic neuralgia); (8) Oral or head and neck surgery within the last 6 months; (9) Pregnant or women in the perinatal period; (10) Severe cognitive impairments or inability to cooperate during assessment; (11) MRI contraindications: such as metal cardiac pacemakers, implantable defibrillators, brain metal implants, claustrophobia. 2. Exclusion criteria for healthy participants (1) MRI contraindications: such as metal cardiac pacemakers, implantable defibrillators, brain metal implants, claustrophobia; (2) Use of antipyretic analgesics, sleeping aids, hormonal medications, or agents affecting the central nervous system within the last week; (3) History of cardiovascular, central nervous system tumors, mental illnesses, or head trauma; (4) History of chronic pain (such as fibromyalgia, chronic headaches, postherpetic neuralgia); (5) Pregnant or women in the perinatal period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gray Matter Volume (GMV)/Gray Matter Concentration (GMC);Central Metabolite Levels;Resting-State Brain Function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale;Concise McGill Pain Questionnaire results;Central Sensitization Scale score;Generalized anxiety scale score;Patient Health Questionnaire Depression Scale score;Oral Health Impact Scale score;Pittsburgh Sleep Quality Index Scale score; | — |
Countries
China
Contacts
Public ContactGuoyao Tang
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed